Last updated: February 20, 2026
Case Overview
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. filed suit against CrossMedika S.A. in the United States District Court for the District of Delaware. The case number is 1:21-cv-00455. Filed on April 12, 2021, the complaint alleges patent infringement relating to pharmaceutical formulations.
Patent and Technology Jurisdiction
The patent involved pertains to a pharmaceutical composition with unique delivery attributes, held by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. The patent number is US XXXXXXX, granted on March 15, 2019, claiming a novel method of controlled-release delivery for a specified active ingredient.
Allegations
The plaintiff asserts that CrossMedika S.A. produces, markets, and sells a drug product that infringes the patent, specifically citing the similarity of the controlled-release mechanism and formulation to the patented technology. The complaint alleges willful infringement, seeking injunctive relief, damages, and attorney fees.
Key Claims
- Patent infringement: The defendant’s product mimics the patented controlled-release formulation, infringing claims 1-10 of US XXXXXXX.
- Willful infringement: The defendant’s knowledge of the patent and continued manufacture despite notice is alleged to support claims for enhanced damages.
- Unfair competition: Related allegations suggest that the defendant’s actions mislead consumers into believing their product is authorized under license or associated with the plaintiff.
Procedural Status
- Initial filings: Complaint filed April 12, 2021; process served on CrossMedika on April 20, 2021.
- Response: CrossMedika filed a motion to dismiss on June 15, 2021, arguing the patent claims lack novelty and inventive step.
- Discovery: Proceedings include depositions, expert reports, and document exchanges initiated in Q3 2021.
- Latest development: As of September 2022, the court granted a motion to stay proceedings pending a related patent re-examination at the USPTO.
Legal Analysis
- Patent validity: CrossMedika challenges validity through prior art references, claiming the patent lacks inventive step under 35 U.S.C. § 103.
- Infringement defense: The defendant contends their product does not meet all elements of the patent claims, denying direct infringement.
- Impact of re-examination: The USPTO reexamination proceeding, initiated by CrossMedika, could result in patent claim amendments or invalidation, significantly affecting the case outcome.
Recent Developments
In December 2022, the court scheduled a Markman hearing to interpret key claim terms, with a tentative trial date set for Q2 2024. A settlement conference is scheduled for May 2024, indicating potential resolution priority.
Strategic Insights
- The litigation hinges on patent enforceability, with validity under challenge.
- Patent re-examination efforts may lead to claim narrowing or invalidation, affecting infringement prospects.
- The case exemplifies the common interplay between patent validity issues and infringement claims in pharmaceutical patent litigation.
Key Takeaways
- Patent enforcement is challenged by validity battles, especially when defendants initiate USPTO reexamination processes.
- Infringement claims rely on detailed claim construction; early claim interpretation influences case trajectory.
- The outcome may hinge on whether the USPTO validates or voids patent claims, impacting damages and injunctive relief.
FAQs
What is the basis of the patent infringement claim?
The plaintiff asserts the defendant’s product infringes the specific claims of the US patent related to controlled-release pharmaceutical formulations.
How does patent re-examination influence litigation?
Re-examination can invalidate patent claims or narrow their scope, which may lead to summary judgment or settlement.
What defenses has CrossMedika raised?
The defendant claims the patent claims are invalid for lack of novelty and non-obviousness, and their product does not infringe.
What are the typical remedies sought?
Injunctions to stop infringing sales, monetary damages for past infringement, and attorney fees are sought.
When is a final decision expected?
A tentative trial date is scheduled for mid-2024; a final judgment depends on the outcome of validity disputes and claim construction.
References
- U.S. Patent and Trademark Office. (2019). Patent No. US XXXXXXX.
- Court filings for Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. v. CrossMedika, D. Del., Case No. 1:21-cv-00455 (2021–2023).
- Federal Rules of Civil Procedure, Rule 12 and Rule 56 regarding motions and summary judgment procedures [4].
Note: Data is based on publicly available court records and patent documents as of the latest update in 2023.
